Fluid amyloid-β (Aβ) biomarkers reflect early β-sheet-rich Aβ deposition during the preclinical stage in Alzheimer's disease model 5XFAD mice
- 1 October 2026
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 408, 116044
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulationAlzheimer's & Dementia, 2025
- Plasma Aβ 42 /Aβ 40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrumAlzheimer's & Dementia, 2024
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Age-related changes in species-typical behaviours in the 5xFAD mouse model of Alzheimer’s disease from 4 to 16 months of ageBehavioural Brain Research, 2024
- Blood-based Aβ42 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for preventionActa Neuropathologica, 2022
- Staging of Alzheimer’s disease: past, present, and future perspectivesTrends in Molecular Medicine, 2022
- Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- CSF biomarkers of Alzheimer's disease concord with amyloid‐β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohortsAlzheimer's & Dementia, 2018
- Alzheimer’s disease: experimental models and realityActa Neuropathologica, 2016
- Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)Neuron, 1994